Please select a day:
02.10.2013
03.10.2013
04.10.2013
05.10.2013
Search

Personal programme
Please enter your email address here in order to bring up your personal programme






Search result



Search Result: Abstracts

Thursday, October 03, 2013

15:45 - 17:00 Poster Session : Inflammation and tissue damage
Predicting brain volume loss at two years as a function of MRI activity in the first year with laquinimod P 361
M. Rocca, G. Comi, D. Jeffery, L. Kappos, X. Montalban, A. Boyko, T. Gorfine, Y. Sidi, M. Filippi (Milan, IT; Advance, US; Basel, CH; Barcelona, ES; Moscow, RU; Petach Tiqva, Netanya, IL)
15:45 - 17:00 Poster Session : Tools for detecting therapeutic response
Bayesian analysis of laquinimod's effect on relapses and disability P 606
G. Cutter, G. Comi, T. Vollmer, D. Ladkani, N. Sasson, V. Knappertz (Birmingham, US; Milan, IT; Aurora, US; Petah Tikva, Netanya, IL; Düssseldorf, DE / Frazer, US)
15:45 - 17:00 Poster Session : Immunomodulation/Immunosuppression
Laquinimod interferes with the development of follicular helper T cells and germinal center B cells in CNS autoimmunity P 560
M. Varrin-Doyer, U. Schulze-Topphoff, K. Pekarek, S. Zamvil (San Francisco, US)
15:45 - 17:00 Poster Session : Immunomodulation/Immunosuppression
Dendritic cells are specifically affected by different immunomodulatory treatment strategies in multiple sclerosis P 516
K. Thomas, T. Sehr, U. Hainke, T. Schultheiss, T. Ziemssen (Dresden, DE)
15:45 - 17:00 Poster Session : Experimental models
A new, targetted animal model of multiple sclerosis in the common marmoset P 376
W. Brück, E. Garea-Rodriguez, L. Hayardeny, C. Wegner, R.M. Stassart, C. Schlumbohm, E. Fuchs (Göttingen, DE; Netanya, IL)
15:45 - 17:00 Poster Session : Neuroprotection
Preventive laquinimod treatment reduces cuprizone-induced pathology in wild type and TLR4-deficient mice P 571
N. Kramann, L. Hayardeny, R. Pförtner, U.-K. Hanisch, W. Brück, C. Wegner (Göttingen, DE; Netanya, IL)
15:45 - 17:00 Poster Session : Neuroprotection
Mechanisms of laquinimod in multiple sclerosis: focus on microglia P 572
M. Mishra, C. Silva, J. Wang, V. Yong (Calgary, CA)
15:45 - 17:00 Poster Session : Immunomodulation/Immunosuppression
Laquinimod modulates inflammation in peripheral blood of relapsing remitting multiple sclerosis patients P 546
R. Zilkha-Falb, M. Gurevich, L. Hayardeny, A. Achiron (Ramat-Gan, Petach-Tikva, IL)
15:45 - 17:00 Poster Session : Others
Which drugs are most effective for relapsing remitting multiple sclerosis? A network metaanalysis of disease modifying therapies P 628
E. Fogarty, S. Schmitz, C. Walsh, N. Tubridy, M. Barry (Dublin, IE)
15:45 - 17:00 Poster Session : Inflammation and tissue damage
Laquinimod regulates inflammatory gene induction in a human model of reactive astrogliosis P 364
T. Pham, J. Zhang, J. Seto, B. Hartmann, L. Hayardeny, G. John (New York, US; Netanya, IL)
15:45 - 17:00 Poster Session : Inflammation and tissue damage
Laquinimod prevents NMOIg-induced disease exacerbation in a model of neuromyelitis optica P 365
A. Argaw, L. Asp, J. Zhang, P. Waters, L. Hayardeny, M. Levy, G. John (New York, US; Oxford, GB; Netanya, IL; Baltimore, US)
17:25 - 17:45 Hot Topic 2 : Can immunomodulatory treatment change the natural history of MS? (Hall A)
Use of historical controls to compare treatment effects in MS 136
N. Koch-Henriksen (Copenhagen / Aarhus, DK)

Friday, October 04, 2013

15:30 - 17:00 Poster Session : Long-term treatment monitoring
Results of switching to laquinimod in the open-label extension phase of the BRAVO study P 1055
T. Vollmer, P.S. Sorensen, K. Selmaj, F. Zipp, E. Havrdova, J. Cohen, Y. Sidi, T. Gorfine, D. Arnold for the BRAVO Study Group
15:30 - 17:00 Poster Session : Long-term treatment monitoring
Disease progression in relapse-free patients treated with laquinimod P 1036
G. Comi, T. Vollmer, G. Cutter, N. Sasson, D. Ladkani, T. Gorfine (Milan, IT; Aurora, Birmingham, US; Netanya, Petah Tikva, IL)
15:30 - 17:00 Poster Session : Tools for detecting therapeutic response
Evaluating the relationship between laquinimod's effects on relapse and disability progression P 1080
M.P. Sormani, G. Cutter, G. Comi, T. Vollmer, P.S. Sorensen, D. Ladkani, N. Sasson, V. Knappertz (Genoa, IT; Birmingham, US; Milan, IT; Aurora, US; Copenhagen, DK; Petah Tikva, Netanya, IL; Düsseldorf, DE / Frazer, US)
15:30 - 17:00 Poster Session : Long-term treatment monitoring
Multicentre, randomized, placebo controlled study to evaluate the efficacy, safety and tolerability of two doses of oral laquinimod (0.6mg/day and 1.2mg/day) for the treatment of patients with relapsing remitting multiple sclerosis P 1054
T. Vollmer, X. Montalban, G. Comi, T. Ziemssen, A. Boyko, P. Vermersch, N. Sasson, T. Gorfine, V. Knappertz, M. Filippi (Aurora, US; Barcelona, ES; Milan, IT; Frankfurt, DE; Moscow, RU; Lille, FR; Netanya, IL; Düsseldorf, DE/ Frazer, US)
15:30 - 17:00 Poster Session : Long-term treatment monitoring
The risk of disability progression is associated with multiple sclerosis functional composite (MSFC) scores in the laquinimod phase 3 trials P 1057
P.S. Sorensen, G. Cutter, T. Vollmer, G. Comi, D. Ladkani, N. Sasson, V. Knappertz (Copenhagen, DK; Birmingham, Aurora, US; Milan, IT; Petah Tikva, Netanya, IL; Düsseldorf, DE / Frazer, US)
15:30 - 17:00 Poster Session : Immunomodulation/Immunosuppression
Laquinimod induces a shift in natural killer cell populations in mice with experimental autoimmune encephalomyelitis P 980
C. Wegner, M. Ott, L. Hayardeny, B. T. Lund, S. Nessler, W. Brück (Göttingen, DE; Netanya, IL; Los Angeles, US)
15:30 - 17:00 Poster Session : Immunomodulation/Immunosuppression
Dose-dependent effects of laquinimod in multiple sclerosis patients on the innate immune system P 981
T. Sehr, K. Thomas, M. Marggraf, O. Bar-Ilan, L. Hayardeny , T. Ziemssen (Dresden, DE; Netanya, IL)





show more results